Quintiles Sees Gain From Drugmaker Cost Shift After IPO

Quintiles Transnational Holdings Inc., the contract pharmaceutical company that had its initial public offering today, sees an opportunity in the move by drugmakers to smaller sales forces and more focused research-and-development spending.

As drug companies cut the size of their field force, Quintiles will provide them the flexibility to help sell new medicines with lower fixed costs, Chief Executive Officer Tom Pike said.